Clinical trials: Osteomalacia
X-linked Hypophosphatemic Rickets/Osteomalacia
A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia
Before switching to the post-marketing study: To evaluate the efficacy and safety of KRN23 administered subcutaneously once every 2 weeks in children with X-linked hypophosphatemic rickets/osteomalacia(XLH).
- Trial name
- NCT03233126
- Testing
- KRN23
- Where
- 4 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hypophosphatasia (HPP)
Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
This clinical trial studies the safety and efficacy of asfotase alfa in infants and young children with infantile onset HPP.
- Trial name
- NCT00744042
- Testing
- asfotase alfa
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 11 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Rickets, Osteomalacia
Maternal and Infant Vitamin Status During the First Nine Months of Infant Life
In this study the investigators wanted to assess vitamin D status and possible consequences of low plasma 25-hydroxyvitamin D levels in a population of healthy mothers and their infants, in the community of Aarhus, Denmark.
- Conditions
- Rickets, Osteomalacia, Osteoporosis
- Trial name
- NCT02548520
- Testing
- Blood and breastmilk samples
- Where
- Denmark
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Tumor-Induced Osteomalacia
Al18F-NOTA-LM3 PET/CT in Patients With TIO
This is a pilot study to assess the value of whole-body Al18F-NOTA-LM3 PET/CT in patients with tumor-induced osteomalacia.
- Trial name
- NCT07366099
- Testing
- Diagnostic Test: Al18F-NOTA-LM3, Diagnostic Test: 68Ga-DOTATATE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Tumor Induced Osteomalcia, Osteomalacia
A Natural History Study of Bone and Mineral Disorders
This study has four objectives: 1) to provide investigators the opportunity to study bone specimens from patients with various skeletal diseases; 2) to treat patients with skeletal diseases at the NIH; 3) to expose NIH trainees…
- Conditions
- Tumor Induced Osteomalcia, Osteomalacia, Familial Tumoral Calcinosis
- Trial name
- NCT00024804
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Osteomalacia
Serum Prolidase Activity and the Role of Leptin in Osteomalacia
Evaluation of the change of serum Prolidase and Leptin values in the diagnosis and follow-up of osteomalacia and its clinical usability
- Trial name
- NCT05716750
- Testing
- Vitamin D
- Volunteers
- 38 people
- Sponsor
- TUĞBA ŞAHBAZ
Tumor-Induced Osteomalacia
Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO
This is an open-label whole-body PET/CT study for investigating the value of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in patients with Tumor-induced osteomalacia.
- Trial name
- NCT04689893
- Testing
- 68Ga-Dotatate, 68Ga-DOTA-JR11
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
Hypophosphatasia
Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)
This clinical trial was conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone.
- Trial name
- NCT01163149
- Testing
- asfotase alfa
- Where
- 3 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hypophosphatasia
Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)
This Clinical Trial is being conducted to study Hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone.
- Trial name
- NCT00894075
- Testing
- ENB-0040
- Sponsor
- Alexion Pharmaceuticals, Inc.
Tumor Induced Oncogenic Osteomalacia
Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic Osteomalacia
The tumors that cause oncogenic osteomalacia (TIO) express and release in the circulation phosphaturic factors such as fibroblast growth factor-23 (FGF-23) that decrease renal phosphate absorption through acting in the proximal…
- Trial name
- NCT02331966
- Where
- Greece
- Volunteers
- 10 people
- Sponsor
- AHEPA University Hospital